Our results revealed that EGFR and HER2 FolTAC-dual v1.0 and Trastuzumab specifically inhibit SKBR3-WT cancer cells while sparing HFF-1 cells (Fig. 4d, e). The gene discussed is EGFR; the disease is cancer.